国泰海通证券研究·2026-03-09 14:03Group 1: AI in Pharmaceutical Industry - The integration of AI in drug development is transitioning from concept to practical validation, significantly enhancing molecular design efficiency and shortening research and development cycles [3] - Companies like JingTai Technology and Insilico Medicine are leveraging AI to create data-driven closed-loop systems, focusing on collaboration and incubation to advance multiple drug pipelines into clinical stages [3][4] - Multinational corporations are upgrading AI from a tool to a foundational infrastructure in research and production, with 2025-2026 identified as a critical period for increased AI investment through mergers and acquisitions [4] Group 2: Investment Opportunities in Power and Computing - The concept of "computing and electricity synergy" has been included in government reports, emphasizing the construction of large-scale intelligent computing clusters and the integration of power systems [8][15] - Companies like China Energy Construction are actively participating in national projects, investing significantly in smart energy solutions and demonstrating leadership in high-voltage design and construction [8][9] - The A-share computing industry is shifting its investment logic from "computing scale expansion" to "power-computing synergy efficiency," with a notable increase in AI computing power expected in the coming years [15]